Talaris Therapeutics has restarted its organ transplant trial after being assured that the circumstances behind a patient’s death this week won’t reoccur.

Pfizer may have dodged a bullet by walking away from AM-Pharma. The biotech, a onetime takeover target for the Big Pharma, has stopped a phase 3 clinical trial of its kidney injury candidate early after it failed an interim futility analysis.

The Association of Clinical Research Organizations (ACRO) rolled out a new element to its toolkit for decentralized clinical trials as part of the trade group’s efforts to speed adoption of digital and hybrid approaches.

As research mounts that the human microbiome influences everything from oral health to gut health to mental health, scientists are discovering that cancers are home to microbes, too. Studies published just in the past few years have shown that bacteria and fungi both infiltrate the tumor microenvironment, driving cancer metastasis and even making it resistant to chemotherapy.

Just a few weeks after racking up its fifth Class I recall from the FDA this year, Philips has hit the half-dozen mark.

Uganda is implementing another measure to combat the current Ebola outbreak, with plans to dole out investigational vaccines in about two weeks, according to media reports.

Hugo is going on a whirlwind international tour. Medtronic’s modular surgical robot has received a series of new regulatory approvals the company says will greatly expand access to the system across Europe, Canada and Japan.

The FDA has pumped the brakes on PTC Therapeutics’ Huntington’s disease trial in the U.S. even as studies kick into gear in other countries.

Tuberculosis has become increasingly difficult to treat as antibiotic resistance rises and the pipeline of antibiotics in development thins out. Now, Merck & Co. and the Bill & Melinda Gates Medical Research Institute are teaming up to tackle the challenge, inking a global licensing deal for two preclinical tuberculosis (TB) antibiotics with hopes of combating resistance and cutting treatment times.

Though it discontinued the recall-ridden HeartWare Ventricular Assist Device over a year ago, Medtronic is still grappling with the heart pump’s many issues as part of its pledge to continue providing support to the approximately 4,000 patients still implanted with the device.